

Dr. Roger Flugel Joins ProteoTech as Chief Business Officer and Dr. Joann Data Joins as Chief Medical Officer

KIRKLAND, Wash., April 25, 2014- ProteoTech Inc. (ProteoTech) today announced that Dr. Roger Flugel has joined ProteoTech as Chief Business Officer, and Dr. Joann Data has joined ProteoTech as Chief Medical Officer.

Dr. Roger Flugel was previously CEO of TheraVida (Mountain View, CA) from 2007 to 2013 and prior to that was a Principal with Sanderling Ventures, serving in a variety of roles as Director, Chairman, CEO, and board observer of several portfolio companies. While at Sanderling, he helped complete strategic corporate transactions for Kadmus (acquired by Schering-Plough, now Merck) and Aderis (acquired by Schwarz Pharma, now UCB). Prior to Sanderling, Dr. Flugel served as the Director of Venture Analysis at HealthCare Ventures. Dr. Flugel is now responsible for representing ProteoTech in all business transactions and partnerships. Dr. Flugel received his Ph.D. in Biophysics from Harvard University, conducting his research in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Dr. Joann Data has held many clinical and regulatory affairs positions at a variety of different biotechnology and pharmaceutical companies, including most recently Amylin Pharmaceuticals, where she served as Senior Vice President of Corporate Assignments as well as Senior Vice President of Regulatory Affairs and Quality Assurance. She was the Executive Vice President of Product Development and Regulatory Affairs for CoCensys and Corporate Vice President for Worldwide Pharmaceutical Regulatory Affairs and Project Management at the Upjohn Company. Dr. Data has been a consultant full time since 2006 within the biotech arena and venture capital groups. She has served as Chief Medical Officer to CoDa Therapeutics, Xytis, Cortex and other biotech companies. Dr. Data has also served on the Board of Directors of Nventa and is currently serving on the advisory boards of Washington University School of Medicine and Vanderbilt University School of Medicine. Data received her M.D. at Washington University School of Medicine and her house officer training in Internal Medicine at the State University of New York at Buffalo followed by her Ph.D. in Pharmacology and Fellowship in Clinical Pharmacology at Vanderbilt.

ProteoTech is a private, therapeutic development Company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolded protein disorders and amyloid diseases. ProteoTech's lead small molecule compound, Systebryl™ (PTI-110) will soon be entering Phase 1/2 proof-of-concept studies in AL (immunoglobulin light chain) amyloidosis (an orphan disease). Other drugs in the pipeline, include a small molecule drug inhibitor for TTR (transthyretin) amyloidosis, a small molecule drug inhibitor of alpha-synuclein accumulation (for Parkinson's disease and other synucleinopathies), and a small molecule drug that works both on the beta-amyloid protein and tau protein of Alzheimer's disease. For further information, please contact Dr. Roger Flugel, Chief Business Officer (flugel@proteotech.com) or Dr. Alan Snow, President & CSO (snow@proteotech.com).